Lacking of database focusing on the mutation markers of anti-cancer drug sensitivity limited the investigation of patterns for mutation markers. We developed construct an infrastructure to highly operable and quick access to data of drug sensitivity mutation markers. The dbMCS mainly consists of five parts: Home, About, Submit, Download and Contact. Users can use keywords to quickly determine whether a cancer caused by a genetic mutation responds to an anticancer drug. Each association in the database contains information of gene, cancer type, mutation, drug response, etc., and relevant references are also provided for each independent item. The database will be of great importance for tackling the problem of drug sensitivity prediction and biomarker identification in cancers.

According to Human Genome Variation Society nomenclature, we standardized the variant descriptions for all three levels (gDNA, cDNA and protein) using TransVar (https://bioinformatics.mdanderson.org/transvar). To acquire standard disease terminology, we mapped the related disease onto Disease Ontology (https://disease-ontology.org). For the drugs involved in the database, we get the standard drug names in DrugBank (https://go.drugbank.com). Users can query and browse the detailed information of each index, and also link to the above useful public resources.

The dbMCS requires a modern web browser with JavaScript and cookies enabled. To view the complex details, pop-ups must not be blocked. The following browsers have been thoroughly tested with dbMCS:

• Mozilla Firefox, version 7 or above
• Internet Explorer, versions 11 or above
• Chrome, version 8 or above

The latest version of Firefox and Chrome is recommended for visualization.

Levels of evidence for entries in dbMCS.

Level NO.	Category	Definition
Level 1	Approved	Items associated with FDA-approved and international guidelines.
Level 2	Clinical	Items associated with clinical trials such as Phase I, Phase II, Phase III, clinical study and so on.
Level 3	Preclinical	Items associated with in preclinical experiments such as preclinical-cell culture, preclinical-PDX, preclinical-cell line xenograft and so on.

• The users can browse the data about the mutation markers of anti-cancer drug sensitivity by key words, disease, gene, cDNA and drug.
• The users can easily apply the search function supporting fuzzy query to acquire what interested in the cancer research field.
• For the locations of mutation and protein domains, dbMCS provides direct visualization.
• The users can freely download the standardized data which are valuable for clinical treatment of cancer.
• The users can submit new data to us for expending the database.

In dbMCS, we tried to make it powerful and convenient to be used. This Usage is prepared for the online service.

Capitalised titles correspond to column headings in the web page tables:

• GENE: The official gene symbol
• DISEASE: disease terminology in Disease Ontology
• DOID: Disease Ontology identifier
• DRUG: The uniform drug names in DrugBank
• Type: missense, FS-indel, duplication or complex-indel (insertion occurs simultaneously with deletion)

(A) Statistics in dbMCS

Gene	Mutation	Disease	Reference	Drug	Sensitivity Entry	Resistance Entry
146	1271	185	1306	486	3151	1276

(B) Type distribution

Type	Number	Type	Number
Missencse	978	Copy number gain	46
IF-deletion	61	Copy number loss	1
IF-insertion	35	Nonsense	31
FS-deletion	6	Synonymous	16
FS-insertion	7	Noncoding	4
Duplication	19	Other	27
Complex-indel	40	Total	1271

The current version number is 1.0 - January, 2021. The most recent update to data was on January 6th, 2021.